0001209191-23-040344.txt : 20230630 0001209191-23-040344.hdr.sgml : 20230630 20230630164309 ACCESSION NUMBER: 0001209191-23-040344 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230628 FILED AS OF DATE: 20230630 DATE AS OF CHANGE: 20230630 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aguilar Richard CENTRAL INDEX KEY: 0001865481 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39289 FILM NUMBER: 231062354 MAIL ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cano Health, Inc. CENTRAL INDEX KEY: 0001800682 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 BUSINESS PHONE: 2034227700 MAIL ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 FORMER COMPANY: FORMER CONFORMED NAME: Jaws Acquisition Corp. DATE OF NAME CHANGE: 20200121 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-28 0 0001800682 Cano Health, Inc. CANO 0001865481 Aguilar Richard CANO HEALTH, INC. 9725 NW 117TH AVENUE MIAMI FL 33178 0 1 0 0 Chief Clinical Officer 0 Class A Common Stock 2023-06-28 4 S 0 150000 1.222 D 1613984 D Class A Common Stock 2023-06-29 4 S 0 400000 1.3144 D 1213984 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.24. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.30 to $1.345. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ David J. Armstrong, Attorney-in-Fact 2023-06-30